Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elizabeth Garrett-Mayer

Showing results (261-270 of 275) with videos related to

Pageof 28
Sort By:
JCO Precision Oncology|October 16, 2024
Palbociclib in Patients With Head and Neck Cancer and Other Tumors With <i>CDKN2A</i> Alterations: Results From the Targeted Agent and Profiling Utilization Registry StudyFrancis P Worden, Evan Pisick, Michael Rothe, et al.
Cancer Immunology, Immunotherapy : CII|December 22, 2017
Correction to: Clinical and immunologic evaluation of three metastatic melanoma patients treated with autologous melanoma-reactive TCR-transduced T cellsTamson Moore, Courtney Regan Wagner, Gina M Scurti, et al.
Breast Cancer Research and Treatment|October 29, 2018
Advanced glycation end products are elevated in estrogen receptor-positive breast cancer patients, alter response to therapy, and can be targeted by lifestyle interventionKatherine R Walter, Marvella E Ford, Mathew J Gregoski, et al.
Cell Reports. Medicine|November 10, 2021
Neoadjuvant presurgical PD-1 inhibition in oral cavity squamous cell carcinomaHannah M Knochelmann, Joshua D Horton, Sixue Liu, et al.
JCO Precision Oncology|April 22, 2026
Temsirolimus in Patients With Solid Tumors With <i>PIK3CA</i> Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) StudyEvan Pisick, Michael Rothe, Elizabeth Garrett-Mayer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 27, 2021
A Grant-Based Experiment to Train Clinical Investigators: The AACR/ASCO Methods in Clinical Cancer Research WorkshopDaniel D Von Hoff, Gary M Clark, Charles A Coltman, et al.
Cancer Immunology, Immunotherapy : CII|October 21, 2017
Clinical and immunologic evaluation of three metastatic melanoma patients treated with autologous melanoma-reactive TCR-transduced T cellsTamson Moore, Courtney Regan Wagner, Gina M Scurti, et al.
JCO Precision Oncology|October 16, 2025
Olaparib in Patients With Solid Tumors With <i>BRCA1/2</i> Alterations: Results From The Targeted Agent and Profiling Utilization Registry (TAPUR) StudyTareq Al Baghdadi, Michael Rothe, Pam K Mangat, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 11, 2023
Standardized Definitions for Efficacy End Points in Neoadjuvant Breast Cancer Clinical Trials: NeoSTEEPJennifer K Litton, Meredith M Regan, Lajos Pusztai, et al.
The Lancet. Oncology|April 10, 2018
ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trialJohn M Wrangle, Vamsidhar Velcheti, Manish R Patel, et al.
Pageof 28

Showing results (261-270 of 275) with videos related to

Sort By:
Pageof 28
JCO Precision Oncology|October 16, 2024
Palbociclib in Patients With Head and Neck Cancer and Other Tumors With <i>CDKN2A</i> Alterations: Results From the Targeted Agent and Profiling Utilization Registry StudyFrancis P Worden, Evan Pisick, Michael Rothe, et al.
Cancer Immunology, Immunotherapy : CII|December 22, 2017
Correction to: Clinical and immunologic evaluation of three metastatic melanoma patients treated with autologous melanoma-reactive TCR-transduced T cellsTamson Moore, Courtney Regan Wagner, Gina M Scurti, et al.
Breast Cancer Research and Treatment|October 29, 2018
Advanced glycation end products are elevated in estrogen receptor-positive breast cancer patients, alter response to therapy, and can be targeted by lifestyle interventionKatherine R Walter, Marvella E Ford, Mathew J Gregoski, et al.
Cell Reports. Medicine|November 10, 2021
Neoadjuvant presurgical PD-1 inhibition in oral cavity squamous cell carcinomaHannah M Knochelmann, Joshua D Horton, Sixue Liu, et al.
JCO Precision Oncology|April 22, 2026
Temsirolimus in Patients With Solid Tumors With <i>PIK3CA</i> Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) StudyEvan Pisick, Michael Rothe, Elizabeth Garrett-Mayer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 27, 2021
A Grant-Based Experiment to Train Clinical Investigators: The AACR/ASCO Methods in Clinical Cancer Research WorkshopDaniel D Von Hoff, Gary M Clark, Charles A Coltman, et al.
Cancer Immunology, Immunotherapy : CII|October 21, 2017
Clinical and immunologic evaluation of three metastatic melanoma patients treated with autologous melanoma-reactive TCR-transduced T cellsTamson Moore, Courtney Regan Wagner, Gina M Scurti, et al.
JCO Precision Oncology|October 16, 2025
Olaparib in Patients With Solid Tumors With <i>BRCA1/2</i> Alterations: Results From The Targeted Agent and Profiling Utilization Registry (TAPUR) StudyTareq Al Baghdadi, Michael Rothe, Pam K Mangat, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 11, 2023
Standardized Definitions for Efficacy End Points in Neoadjuvant Breast Cancer Clinical Trials: NeoSTEEPJennifer K Litton, Meredith M Regan, Lajos Pusztai, et al.
The Lancet. Oncology|April 10, 2018
ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trialJohn M Wrangle, Vamsidhar Velcheti, Manish R Patel, et al.
Pageof 28